NiTi steps up ColonRing roll-out with $18.5m
This article was originally published in Clinica
NiTi Surgical Solutions is to accelerate marketing and commercialisation of its CE-marked and FDA-cleared ColonRing wound closure device, following an $18.5m series F financing round. Lead investor in the fundraising was Forbion Capital Partners (Naarden, the Netherlands); subsequently, Forbion venture partner Dr Avi Molcho will join NiTi’s board of directors. NiTi’s existing investors – Evergreen Venture Partners, Israel Healthcare Ventures, MBVC and Alice Lab, and SCP Vitalife – also participated in the financing.